Overview
Respiratory Syncytial Virus (RSV), historically known as a pediatric illness, is now increasingly affecting **adults—particularly the elderly and immunocompromised—**in the post-COVID era. Following the disruption of typical viral transmission patterns during the COVID-19 pandemic (due to lockdowns, masking, and distancing), population-wide immunity to RSV has declined, resulting in unexpected outbreaks and more severe disease in adults.

Causes

• Immunity Gap: Reduced RSV circulation during the pandemic led to decreased natural immune boosting, especially in older adults.
• Increased Susceptibility: Adults with comorbidities or weakened immune systems (e.g., transplant recipients, cancer patients) are more vulnerable.
• Immune Rebound Effect: Sudden re-exposure to RSV post-pandemic is triggering more symptomatic infections.
• Co-infection Risks: Some individuals are presenting with co-infections of RSV, influenza, or SARS-CoV-2, complicating diagnosis and treatment.
• Population Aging: A growing elderly population globally means more people at risk for severe RSV-related complications.

Symptoms in Adults

• Nasal congestion and runny nose
• Sore throat and persistent cough
• Fatigue, body aches, and low-grade fever
• Wheezing and difficulty breathing (especially in those with asthma, COPD, or heart disease)
• In severe cases: bronchitis, pneumonia, or hospitalization

High-Risk Groups

• Adults over 65
• People with chronic respiratory or cardiovascular conditions
• Immunocompromised individuals
• Residents of long-term care facilities
• Healthcare workers with repeated exposure

Diagnosis

• PCR Testing: Most accurate method to confirm RSV infection.
• Rapid Antigen Tests: Available but less sensitive in adults than in children.
• Chest X-ray or CT: To assess for pneumonia or lung involvement in severe cases.
• Rule Out COVID-19 or Influenza: Especially during peak respiratory virus seasons.

Treatment

• Supportive Care: Hydration, rest, and symptom relief with antipyretics and cough suppressants.
• Oxygen Therapy: For those with low oxygen levels or respiratory distress.
• Antiviral Therapies: Still limited for RSV in adults; investigational drugs are under development.
• Hospitalization: May be required for high-risk or severely ill patients.

Prevention

• RSV Vaccines for Older Adults:
  • Approved vaccines (e.g., Arexvy and Abrysvo) are now recommended for adults 60+ in many countries.
  • Targeted vaccination campaigns are especially important in fall/winter seasons.
• Infection Control: Masking, hand hygiene, and isolating symptomatic individuals.
• Avoiding Crowded Indoor Spaces: Especially during respiratory virus surges.
• Monoclonal Antibodies: Being developed for high-risk adult populations, similar to those used in infants.

Prognosis
Most healthy adults recover from RSV within 1–2 weeks. However, older adults and those with chronic conditions may experience severe complications, prolonged illness, or secondary infections. Mortality rates in hospitalized elderly RSV patients can be significant, similar to those of seasonal influenza.

Global Trends

• RSV hospitalizations in adults have surged post-COVID, especially in North America, Europe, and East Asia.
• Countries with aging populations and low RSV vaccine uptake are reporting higher morbidity.
• RSV is now being included in respiratory surveillance systems alongside COVID-19 and influenza.